Currently, LambdaVision is partnering with Space Tango, with funding from NASA, to explore the benefits of microgravity for producing the artificial retina on the International Space Station U.S. National Laboratory (ISS) that is currently orbiting the Earth. This artificial retina is one of the first technologies being produced on the ISS that has potential for clinical use. While this therapy can be effectively developed in labs on Earth, producing the artificial retina in low-Earth orbit (LEO), improves the homogeneity of the alternating protein and polymer layers, resulting in increased stability, performance, and optical quality of the multi-layer system. These improvements could reduce the amount of materials required to produce the artificial retina, lower costs, and accelerate production time for future pre-clinical and clinical efforts.

LambdaVision, together with Space Tango, will carry out a series of flights to the ISS to evaluate and improve production processes, produce artificial retinas that can be use in pre-clinical, as well as early stage clinical testing, and define parameters for commercial-scale production. The company intends to initiate clinical trials by 2024 for the treatment of advanced RP, and following initial success in treating this rare disease, will expand to investigate the use of the product in AMD.

Skip to content